A sensitive method for the quantification of fluticasone propionate in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionisation mass spectrometry.
A highly sensitive and selective method has been developed for the quantification of fluticasone propionate (FP) in human plasma. The drug was isolated from human plasma using C18 solid-phase extraction cartridges. The analysis was based on high-performance liquid chromatography/atmospheric pressure chemical ionisation mass spectrometry (HPLC/APCI/MS), using the 22R epimer of budesonide (BUD) acetate, synthesised using acetic anhydride, as internal standard. The mass spectrometer was operated in APCI mode with selected ions at tune masses of 473.2 and 501.2 m/z, corresponding to the MH+ of acetylated (22R)BUD and FP, respectively. The mobile phase used was a mixture of 50% ethanol in water with a flow rate of 0.45 ml min-1. The system was optimised by tuning the capillary and tube lens with a concentrated solution of FP. The recovery of FP from human plasma was 86.3%. Linearity of response was obtained over the concentration range 0.2-4.0 ng ml-1. The intra-assay and inter-assay variability were 6.3 and 2.9%, respectively. The lower limit of quantification was 0.2 ng ml-1 when a solid-phase extraction preceded the HPLC/APCI/MS.
Li
Y N
YN
Department of Pharmacy, University of Sydney, Australia.
Tattam
B N
BN
Brown
K F
KF
Seale
J P
JP
D000730:Androstadienes / Q000097:blood*; D000893:Anti-Inflammatory Agents / Q000097:blood*; D002138:Calibration; D002851:Chromatography, High Pressure Liquid; D000068298:Fluticasone; D006801:Humans; D013058:Mass Spectrometry; D015203:Reproducibility of Results
D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D000068298:Fluticasone